Ligand signs research, licensing deal with Omthera for new dyslipidemia treatment
The research deal will target the development of new products that use the proprietary Ligand-developed LTP TECHNOLOGY to improve lipid-lowering activity of certain omega-3 fatty acids. Ligand president
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.